Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Day

Showing results (1291-1300 of 1,311) with videos related to

Pageof 132
Sort By:
Acta Neuropathologica|June 3, 2025
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer diseaseCharles D Chen, Erin E Franklin, Yan Li, et al.
The Lancet. Neurology|April 17, 2024
Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional studyJulie K Wisch, Nicole S McKay, Anna H Boerwinkle, et al.
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 27, 2023
Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's diseaseSára Nemes, Paige E Logan, Mohit K Manchella, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 9, 2023
Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohortAngelina J Polsinelli, Ryan J Wonderlin, Dustin B Hammers, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trialAustin McCullough, Charles D Chen, Brian A Gordon, et al.
JAMA Neurology|April 15, 2024
Clinicopathologic Heterogeneity and Glial Activation Patterns in Alzheimer DiseaseNaomi Kouri, Isabelle Frankenhauser, Zhongwei Peng, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 10, 2023
Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)Hanna Cho, Nidhi S Mundada, Liana G Apostolova, et al.
JMIR Aging|June 26, 2024
Examining Associations Between Smartphone Use and Clinical Severity in Frontotemporal Dementia: Proof-of-Concept StudyEmily W Paolillo, Kaitlin B Casaletto, Annie L Clark, et al.
Aging Cell|June 9, 2023
Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's diseaseStephanie A Schultz, Zahra Shirzadi, Aaron P Schultz, et al.
Pageof 132

Showing results (1291-1300 of 1,311) with videos related to

Sort By:
Pageof 132
Acta Neuropathologica|June 3, 2025
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer diseaseCharles D Chen, Erin E Franklin, Yan Li, et al.
The Lancet. Neurology|April 17, 2024
Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional studyJulie K Wisch, Nicole S McKay, Anna H Boerwinkle, et al.
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 27, 2023
Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's diseaseSára Nemes, Paige E Logan, Mohit K Manchella, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 9, 2023
Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohortAngelina J Polsinelli, Ryan J Wonderlin, Dustin B Hammers, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trialAustin McCullough, Charles D Chen, Brian A Gordon, et al.
JAMA Neurology|April 15, 2024
Clinicopathologic Heterogeneity and Glial Activation Patterns in Alzheimer DiseaseNaomi Kouri, Isabelle Frankenhauser, Zhongwei Peng, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 10, 2023
Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)Hanna Cho, Nidhi S Mundada, Liana G Apostolova, et al.
JMIR Aging|June 26, 2024
Examining Associations Between Smartphone Use and Clinical Severity in Frontotemporal Dementia: Proof-of-Concept StudyEmily W Paolillo, Kaitlin B Casaletto, Annie L Clark, et al.
Aging Cell|June 9, 2023
Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's diseaseStephanie A Schultz, Zahra Shirzadi, Aaron P Schultz, et al.
Pageof 132